Soligenix Inc Dossier - Source-backed chat

Soligenix Inc

SNGXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.61

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.36Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.9M

Enterprise Value −$1.9M

Shares Outstanding 21.8M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Soligenix is undergoing a critical strategic transition following the devastating clinical failure of its lead Phase 3 candidate, HyBryte™ (SGX301), which was halted for futility in April 2026. This setback has removed the primary near-term commercial catalyst and forced management to pivot toward evaluating strategic alternatives, including potential mergers and acquisitions, while re-assessing remaining pipeline assets like SGX945 (dusquetide) for Behçet's Disease. With a cash balance of approximately $6.0 million as of March 31, 2026, providing a runway into the second quarter of 2027, the company faces significant going-concern risks. A 'Hold' rating is recommended as the stock is highly speculative, and investors should wait for clarity on the outcome of the strategic review and potential M&A transactions.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.50

Mean target$1.75

High · most bullish analyst$2.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The bear case involves the inability to secure a strategic transaction, partnership, or additional financing, leading to severe liquidity constraints as the cash runway nears its end in early 2027. This would result in further dilution of existing shareholders, potential delisting from Nasdaq due to bid-price non-compliance, or eventual restructuring/liquidation.

Base CaseCentral scenario

$1.5055%

The base case assumes Soligenix continues to operate as a going concern while actively seeking strategic alternatives. The company will likely experience continued net losses and negative cash flows, utilizing its ATM facility and potential small grants to extend its runway. Pipeline development will remain slow and highly constrained by capital, with the stock trading at depressed levels reflecting high uncertainty.

Bull CaseUpside scenario

$1.5025%

The bull case relies on the successful execution of a strategic transaction (such as a merger or acquisition) that provides immediate capital and operational synergy, or the rapid advancement of SGX945 (dusquetide) for Behçet's Disease under its EMA Orphan Drug and UK MHRA Promising Innovative Medicine (PIM) designations. Additionally, securing non-dilutive funding from organizations like CEPI for the ThermoVax® thermostable vaccine platform could revitalize the company's valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Active evaluation of strategic options, including merger and acquisition opportunities, which could unlock residual asset value.
SGX945 (dusquetide) has demonstrated promising biological efficacy in Phase 2 trials and holds EMA Orphan Drug and UK MHRA PIM designations.
ThermoVax® thermostable vaccine platform remains viable for non-dilutive government and NGO funding (e.g., CEPI proposals for Ebola vaccine).

Key Investment Risks

Going concern risk with a limited cash runway projected only into the second quarter of 2027.
High clinical and regulatory risk following the futility halt of the pivotal Phase 3 FLASH2 trial for HyBryte™.
Potential Nasdaq delisting risk due to bid-price non-compliance and minimum stockholders' equity requirements.
Heavy reliance on highly dilutive equity financing (such as ATM programs) to sustain basic operations.

Thesis Invalidation Triggers

Failure to secure any strategic transaction or partnership by the end of 2026.
Inability to raise additional capital, leading to a cash runway of less than three months.
Receipt of a Nasdaq delisting notice that cannot be cured.
Negative regulatory feedback or clinical setbacks for SGX945 or the vaccine platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.